The global market for ADHD medications

Health Affairs

Volumn 26, Issue 2, 2007, Pages 450-457

  Scheffler, Richard M ^a,b   Hinshaw, Stephen P ^c   Modrek, Sepideh ^d   Levine, Peter ^e  

^a School of Public Health   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Agency for Healthcare Research ^*  (United States)

^d Agency for Healthcare Research   (United States)

^e KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; AUSTRALIA; CANADA; CHILD; COHORT ANALYSIS; COST CONTROL; COST OF ILLNESS; DRUG COST; DRUG UTILIZATION; ECONOMICS; FEMALE; HOSPITALIZATION; HUMAN; MALE; PHARMACOECONOMICS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; UNITED STATES;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUSTRALIA; CANADA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST OF ILLNESS; COST SAVINGS; DRUG COSTS; DRUG UTILIZATION; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; MALE; METHYLPHENIDATE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 33947326094     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.26.2.450     Document Type: Article

References (51)

1. R.A. Barkley, "Attention-Deficit Hyperactivity Disorder," in Child Psychopathology, 2d ed., ed. E.J. Mash and R.A. Barkley (New York: Guilford, 2003), 75-143;
2. and M. Rappley, "Attention Deficit-Hyperactivity Disorder," New England Journal of Medicine 352, no. 2 (2005): 165-173.
3. S. Mannuzza and R.G. Klein, "Long-Term Prognosis in Attention-Deficit/Hyperactivity Disorder," Child and Adolescent Psychiatric Clinics of North America 9, no. 3 (2000): 711-726.
4. S.P. Hinshaw, "Is ADHD an Impairing Condition in Childhood and Adolescence?" in Attention-Deficit Hyperactivity Disorder: State of the Science, Best Practices, ed. P.S. Jensen and J.R. Cooper (Kingston, N.J.: Civic Research Institute, 2002), 5-1-5-21.
5. C. Bradley, "The Behavior of Children Receiving Benzedrine," American Journal of Psychiatry 94 (1937): 577-585;
6. and L.L. Greenhill and B.B. Osman, eds., Ritalin: Theory and Practice (Larchmont, N.Y.: Mary Ann Liebert, 2000).
7. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement, "Clinical Practice Guideline: Treatment of the School-Aged Child with Attention-Deficit/Hyperactivity Disorder," Pediatrics 108, no. 4 (2001): 1033-1044.
8. J.M. Zito et al., "Trends in the Prescribing of Psychotropic Medications to Preschoolers," Journal of the American Medical Association 283, no. 8 (2000): 1025-1030;
9. D.J. Safer, J.M. Zito, and E.M. Fine, "Increased Methylphenidate Usage for Attention Deficit Disorder in the 1990s," Pediatrics 98, no. 6, Part 1 (1996): 1084-1088;
10. and J.M. Zito et al., "Rising Prevalence of Antidepressants among U.S. Youths," Pediatrics 109, no. 5 (2000): 721-727.
11. Centers for Disease Control and Prevention, "Mental Health in the United States: Prevalence of Diagnosis and Medication Treatment for Attention-Deficit/Hyperactivity Disorder - United States, 2003," Morbidity and Mortality Weekly Report 54, no. 34 (2005): 842-847.
12. G. Harris, "Warning Urged on Stimulants Like Ritalin," New York Times, 10 February 2006.
13. H. Upadhyaya et al., "Attention-Deficit/Hyperactivity Disorder, Medication Treatment, and Substance Use Patterns among Adolescents and Young Adults," Journal of Child and Adolescent Psychopharmacology 15, no. 5 (2005): 799-809;
14. and S.E. McCabe, C.J. Teter, and C.J. Boyd, "The Use, Misuse, and Diversion of Prescription Stimulants among Middle and High School Students," Substance Use and Misuse 39, no. 7 (2004): 1095-1116.
15. Safer et al., "Increased Methylphenidate Usage."
16. J. Biederman and S.V. Faraone, "Attention Deficit Hyperactivity Disorder: A Worldwide Concern," Journal of Nervous and Mental Disease 192, no. 7 (2004): 453-454.
17. National Institute for Health and Clinical Excellence, "Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention Deficit/ Hyperactivity Disorder (ADHD) in Childhood," Technology Appraisal Guidance no. 13, October 2000, http://nice.org.uk/pdf/Methylph-guidance13.pdf (accessed 30 January 2007).
18. J. Nigg, What Causes ADHD: Understanding What Goes Wrong and Why (New York: Guilford, 2006).
19. J. Wooldridge, Econometric Analysis of Cross Section and Panel Data (Cambridge, Mass.: MIT Press, 2002).
20. A detailed description of the data construction and methods can be found in the online technical appendix, available at http://content.healthaffairs.org/ cgi/content/full/26/2/450/DC1.
21. We separated Hong Kong and Taiwan from mainland China because this separation is made in the data reporting system.
22. We use the terms usage and volume interchangeably.
23. All growth rates are calculated using the least-squares method described in Section B of the online technical appendix. See Note 15.
24. R. Cooper, T.E. Getzen, and P. Laud, "Economic Expansion Is a Major Determinant of Physician Supply and Utilization," Health Services Research 38, no. 2 (2003): 675-696;
25. and T. Hitiris and J. Posnett, "The Determinants and Effects of Health Expenditure in Developed Countries," Journal of Health Economics 11, no. 2 (1992): 173-181.
26. See Section B of the online technical appendix, as in Note 15.
27. See Section C of the online technical appendix; ibid.
28. Ibid.
29. H.C. Lang, R.M. Scheffler, and T.W. Hu, "ADHD Medications in the U.S. and OECD Countries: Determinants of Quantity and Price," Petris Working Paper no. 100/2006, http://petris.org/project-ADHD_medications_US_OECD. htm (accessed 13 February 2006).
30. "Evaluating Prescription Drugs Used to Treat: Attention Deficit Hyperactivity Disorder - Comparing Effectiveness, Safety, and Price," Consumer Reports Best Buy Drugs, 2005, http://www.crbestbuydrugs.org/ PDFs/ADHDfinal.pdf (accessed 11 December 2006).
31. J.L. Rushton and J.T. Whitmire, "Pediatric Stimulant and Selective Serotonin Reuptake Inhibitor Prescription Trends," Archives of Pediatrics and Adolescent Medicine 155, no. 5 (2001): 560-565.
32. National Center on Addiction and Substance Abuse, "Under the Counter: The Diversion and Abuse of Controlled Prescription Drugs in the U.S.," July 2005, http://www.casacolumbia.org/Absolutenm/articlefiles/380- final_report.pdf (accessed 1 November 2005);
33. and G.T. Ray et al., "Attention-Deficit/Hyperactivity Disorder in Children: Excess Costs Before and After Initial Diagnosis and Treatment Cost Differences by Ethnicity," Archives of Pediatrics and Adolescent Medicine 160, no. 10 (2006): 1063-1069.
34. Nigg, What Causes ADHD.
35. See Section C of the online technical appendix, as in Note 15.
36. "Evaluating Drugs Used to Treat: Attention Deficit Hyperactivity Disorder."
37. R.A. Barkley et al., "International Consensus Statement on ADHD: January 2002," Clinical Child and Family Psychology Review 5, no. 2 (2002): 89-111.
38. J.M. Swanson, M. Lerner, and L. Williams, "More Frequent Diagnosis of Attention Deficit-Hyperactivity Disorder," New England Journal of Medicine 333, no. 14 (1995): 944.
39. H.A. Huskamp et al., "Impact of Three-Tier Formularies on Drug Treatment of Attention-Deficit/Hyperactivity Disorder in Children," Archives of General Psychiatry 62, no. 4 (2005): 435-441;
40. E.R. Berndt, "The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment?" Health Affairs 20, no. 2 (2001): 100-114;
41. and J.M. Zito et al., "Psychotropic Practice Patterns for Youth: A Ten-Year Perspective," Archives of Pediatrics and Adolescent Medicine 157, no. 1 (2003): 17-25.
42. IMS Health, "World Pharma Sales 2001: US Still Driving Growth," http://www.imshealth.com/web/content/0,3148, 64576068_63872702_70260998_70328515,00.html (accessed 1 November 2005).
43. A. Charach et al., "Correlates of Methylphenidate Use in Canadian Children: A Cross-Sectional Study," Canadian Journal of Psychiatry 51, no. 1 (2006): 17-26.
44. L. Sizoo, "Swedish Doctors Wrote Illegal ADHD Prescriptions," Local, 5 February 2005;
45. and C. Frances et al., "Paediatric Methylphenidate (Ritalin) Restrictive Conditions of Prescription in France," British Journal of Clinical Pharmacology 57, no. 1 (2004): 115-116.
46. Frances et al., "Paediatric Methylphenidate (Ritalin) Restrictive Conditions."
47. E. Schirm et al., "Psychotropic Medication in Children: A Study from the Netherlands," Pediatrics 108, no. 2 (2001): E25.
48. D. Bramble, "Annotation: The Use of Psychotropic Medications in Children: A British View," Journal of Child Psychology and Psychiatry 44, no. 2 (2003): 169;
49. and C. Malacrida, "Medicalization, Ambivalence, and Social Control: Mothers' Descriptions of Educators and ADD/ADHD," Health 8, no. 1 (2004): 61-80.
50. Barkley, "Attention-Deficit Hyperactivity Disorder."
51. J.M. Rey and M.G. Sawyer, "Are Psychostimulant Drugs Being Used Appropriately to Treat Child and Adolescent Disorders?" British Journal of Psychiatry 182 (2003): 284-286.